Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study

NCT05669989 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05669989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
April 5, 2023
Completion date
November 30, 2028
Enrollment
70 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma